The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


First-in-man use of the new-generation TriGUARD 3 cerebral embolic protection device during transcatheter aortic valve implantation

EuroIntervention 2018;14:e1178-e1179 published online September 2018 published online e-edition December 2018. DOI: 10.4244/EIJ-D-18-00442

1. Quebec Heart and Lung Institute, Québec, Canada; 2. Columbia University Medical Center, New York, NY, USA

J. Rodés-Cabau holds the Canadian Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions and has received institutional research grants from Edwards Lifesciences, Medtronic and Heart Leaflet Technologies. T. Nazif is an investigator for the TriGUARD 3 US trial. The other author has no conflicts of interest to declare.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Final results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable LOTUS valve system